The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Feb. 07, 2017

Filed:

Oct. 02, 2013
Applicants:

Alan B. Frey, Princeton, NJ (US);

Edwin J. Vazquez-cintron, New York, NY (US);

Ngozi R. Monu, Jersey City, NJ (US);

Jeremy C. Burns, New York, NY (US);

Inventors:

Alan B. Frey, Princeton, NJ (US);

Edwin J. Vazquez-Cintron, New York, NY (US);

Ngozi R. Monu, Jersey City, NJ (US);

Jeremy C. Burns, New York, NY (US);

Assignee:

New York University, New York, NY (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C40B 30/06 (2006.01); G01N 33/50 (2006.01); G01N 33/68 (2006.01); C12Q 1/68 (2006.01); G01N 33/566 (2006.01);
U.S. Cl.
CPC ...
G01N 33/5041 (2013.01); C12Q 1/6809 (2013.01); G01N 33/505 (2013.01); G01N 33/566 (2013.01); G01N 33/6872 (2013.01); C12Q 2600/136 (2013.01); C40B 30/06 (2013.01);
Abstract

Screening assays and methods of using same for screening to identify modulator agents or compounds that affect pcdh18 mediated inhibition of T cell effector function are described herein. Pharmaceutical and immunogenic compositions comprising agents or compounds that modulate pcdh18 mediated inhibition of T cell effector function are also encompassed. Methods for modulating pcdh18 mediated inhibition of T cell effector function using agents identified using assays described herein in pharmaceutical and immunogenic compositions are also envisioned. Adenocarcinoma is an exemplary tumor type that expresses pcdh18 and for which such pharmaceutical and immunogenic compositions would confer benefit to patients. Also encompassed are methods for reducing pcdh18 mediated inhibition of T cell effector function so as to achieve more effective T cell responses to pcdh18 expressing tumors.


Find Patent Forward Citations

Loading…